Topic: combination drugs

3. Vytorin

Merck’s cholesterol drugs Zetia and Vytorin are a franchise, but they’re also distinct meds with different marketing points. Zetia can be added on to any statin. Vytorin combines Zetia with Merck’s off-patent statin Zocor.

2. Zetia

Merck’s big-selling Zetia was launched in 2002, and it did gin up sales quickly; by 2005, Merck and its partner Schering-Plough was reporting $1.5 billion from Zetia. But In 2008, Zetia’s sales fell by 9% to $2.2 billion. Its sales during the final three years of its patent life hovered in the $2.5 billion range.

8. Janumet

Janumet, which combines Merck’s own blockbuster DPP-4 drug Januvia with metformin, reeled in $984 million in U.S. sales in 2016.
Januvia box

2. Januvia

Merck’s Januvia has faced its share of obstacles, but it remains a mainstay of diabetes treatment—and of Merck’s revenue mix. It brought in $3.91 billion worldwide, $2.29 billion of that in the U.S., and that doesn’t include its combo-med cousin, Janumet.

Top 10 diabetes drugs by 2016 sales

Formulary exclusions, pricing, biosimilars and cardiovascular outcomes data have impacted the U.S. diabetes space. We’ve compiled last year’s U.S. sales rankings for you, along with some insight into what to expect for each of the top meds going forward.